John Kachoris, MD
Neurocritical Care · Cincinnati, OHNPI 1073774147
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,775 of the $5,802 with a category attached, or 65.1%. AbbVie accounts for 65.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $3,063 and has fallen 98.5% since, to $45 in 2025. Among neurocritical care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $138.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Ceribell, Inc.$426
- UCB, Inc.$289
- Medtronic$152
- Genentech USA, Inc.$148
- Neurocrine Biosciences, Inc.$137
- plus $855 from 17 others
What the payments were for
- Speaking & faculty fees$3,77565%
- Food & beverage$2,02635%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $3,795 |
| Ceribell, Inc. | 1 | $426 |
| UCB, Inc. | 4 | $289 |
| Medtronic | 1 | $152 |
| Genentech USA, Inc. | 1 | $148 |
| Neurocrine Biosciences, Inc. | 1 | $137 |
| Abbott | 1 | $133 |
| Biohaven Pharmaceuticals, Inc. | 3 | $130 |
| Acorda Therapeutics, Inc | 5 | $128 |
| Boston Scientific | 1 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $111 |
| Sanofi | 2 | $32 |
| Assertio Therapeutics, Inc. | 2 | $27 |
| CSL Behring | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 2 | $23 |
| Biogen | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| GE HealthCare | 1 | $15 |
| Novartis | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Greenwich Biosciences, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$3,750
- Ceribell Rapid Response EEG$426
- Briviact$258
- NURTEC ODT$216
- LINQ II$152
- Activase$148
- INGREZZA$137
- AMPLATZER TALISMAN$133
- Watchman$124
- INBRIJA$102
How this compares
$5,802 in reported general payments places this provider in the 95th percentile of 30 neurocritical care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurocritical care in Cincinnati
- Matthew SmithCincinnati$2K
- Graham GarrisonCincinnati$696
- Christopher ZammitCincinnati$693
- Ren-Shuoh KuoCincinnati$201
- Deep PatelCincinnati$190
- Kiran PoudelCincinnati$145
- David RobinsonCincinnati$126
- Barbara BasilCincinnati$106
- Lachelle VanceCincinnati$59
- Michel TorbeyColumbus$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.